Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment

But beneath the selloff, something unusual has emerged.Novo Nordisk is no longer priced like a hypergrowth AI-era healthcare leader. It's priced like a slow-growth legacy pharma stock.NVO Stock Now Trades At A Fraction Of Peer ValuationsAt just 10.6x earnings, NVO stock trades at a dramatic discount to both obesity-drug rival Eli Lilly and Company and broader pharma peers.CompanyP/E Ratio (TTM)Earnings YieldNovo Nordisk10.6x9.42%Eli Lilly45.4x2.20%Vertex Pharmaceuticals31.8x3.14%Pfizer20.0x5.01%Data Source: ...